Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein disulfide-isomerase A3 (ERp57) is a thiol isomerase belonging to the protein disulfide isomerase (PDI) family, which is essential for platelet activation and the stabilization of thrombi (Wang et al., 2009, PMID: 19381018). Although traditionally recognized as an endoplasmic reticulum-resident chaperone involved in glycoprotein folding, ERp57 is secreted from platelet alpha-granules and translocated to the plasma membrane upon vascular injury (UniProt: P30101). On the platelet surface, it facilitates the activation of key adhesion receptors, most notably integrin alpha-IIb/beta-3 (GPIIb/IIIa), by catalyzing disulfide bond rearrangements (Zhou et al., 2015, PMID: 25631143). This activity is crucial for platelet aggregation and the subsequent growth of a thrombus (Stopa et al., 2017, PMID: 28239653). Given its prominent role in pathological thrombosis, ERp57 is considered a significant therapeutic target for developing next-generation antithrombotic agents (Jasuja et al., 2012, PMID: 22535994). Research indicates that inhibiting ERp57 can reduce thrombus formation with a potentially more favorable safety profile regarding bleeding complications compared to conventional antiplatelet drugs.
Inhibition of the thiol-disulfide exchange activity of ERp57 on the platelet surface, which prevents the conformational change and activation of integrin alpha-IIb/beta-3 (GPIIb/IIIa), thereby reducing platelet aggregation and thrombus stabilization (Wang et al., 2009, PMID: 19381018; Zhou et al., 2015, PMID: 25631143).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein disulfide-isomerase A3 (ERp57) (ERp57).